CVRX reports Q1 2026 results on May 6 carrying fresh short-side momentum, a recent earnings track record of sharp declines, and a stock already down 13% over the past month.
Short sellers have been adding positions with conviction. Short interest climbed 17% over the past week to 6.3% of the free float — a material move in a short window. The ORTEX short score has crept up to 60.9, its highest reading in the ten-day history visible in the data, rising from 57.4 at the start of the week. That directional build matters: while the absolute short interest level is not extreme, the rate of acceleration into the print is notable. The borrow market, however, offers little squeeze threat. Cost to borrow is a modest 0.60%, down roughly 20% on the week and more than 50% below its level a month ago. Availability remains comfortable, meaning the recent short-side buildup is happening in a liquid lending environment with no meaningful friction.
Options positioning tells a slightly more cautious story — but only slightly. The put/call ratio is running above its 20-day average, at 0.29 versus a mean of 0.25, placing it about one standard deviation above normal. That hints at a modest tilt toward downside protection, though the reading is still far from the defensive extremes the stock has seen over the past year (the 52-week PCR high was 0.64). Neither the options market nor the borrow market is signalling imminent squeeze or panic — the setup is mildly guarded rather than overtly bearish.
The bull-bear debate turns on reimbursement trajectory and the durability of early 2026 momentum. Bulls point to the 14.5% year-over-year revenue growth and 85% gross margins in Q1, along with Medicare Advantage prior authorisation approval rates rising to 50% from 44% in 2025 — a structural tailwind for Barostim neo adoption. The case for patience also rests on 252 active U.S. implanting centres, though bears note that active accounts have been slipping below estimates. The deeper bear concern is the company's persistent net losses and a path to profitability that remains distant. Analyst consensus skews positive — Canaccord Genuity kept its Buy and $10 target as recently as April 14 — but the mean price target of $11.17 implies meaningful upside only for those willing to look past near-term losses, and JPMorgan, which downgraded to Underweight in May 2025, remains a visible anchor on the bearish side.
History adds a stark reference point. The last print, in February, produced an 18.6% single-day drop followed by a further 13.2% loss over five days — the kind of reaction that naturally encourages investors to hedge or step aside ahead of the next release. The print on May 6 will test whether the Q1 revenue and margin beat described in the bull case is enough to interrupt that recent pattern, or whether persistent losses and softening active account trends keep the stock on the defensive trajectory it has followed since late 2025.
See the live data behind this article on ORTEX.
Open CVRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
